Richter S, Vardi Y, Ringel A, Shalev M, Nissenkorn I
Department of Urology, Sapir Medical Center, Kfar Sava, Sackler Faculty of Medicine, University of Tel Aviv, Israel.
Int J Impot Res. 2001 Jun;13(3):172-5. doi: 10.1038/sj.ijir.3900672.
The objective of this work was to determine the effectiveness of intracavernous injections (ICI) of vasoactive drugs in elderly men with erectile dysfunction and to compare the results obtained with the injection of two different drug combinations. It was a case control study. The sample consisted of 300 men, 63-85 y of age (mean 67.1) with erectile dysfunction of organic origin. Among the patients 180 underwent first trial with injection of prostaglandin E1 (PE). Further on these 180 patients and another 120 (in total 300 patients) were treated with a triple combination of papaverine hydrochlorate, phentolamine messylate and prostaglandin E1 (PPR). The number of responders to the injection of either PE alone or the drug combination was recorded. The quality of the erections was evaluated in the outpatient clinic by the medical staff and through patient's report after home trial. The average volume of either PE or PPR necessary to obtain a functional erection was measured. We observed a statistically significant association between the results obtained after the injection of PPR as compared to PE (chi2 with 2 d.f.: 34.666; P= < 0.001). A functional erection was obtained in 224/300 (74.7%) after the injection of PPR as compared to 87/180 men (48.3%) treated with PE. The average volume of PPR necessary to obtain a functional erection was 0.35+/-0.14 ml whereas that of PE was 1.3+/-0.3 ml. intracavernous injection of vasoactive drugs is still one of the most successful therapies for patients suffering from organic impotence. It is less effective in the older age group as compared to younger. However, if this form of therapy is chosen for aged men the triple combination therapy (PPR) yields a higher response rate than that obtained with prostaglandin alone.
这项工作的目的是确定血管活性药物海绵体内注射（ICI）对老年勃起功能障碍男性的有效性，并比较两种不同药物组合注射所获得的结果。这是一项病例对照研究。样本包括300名年龄在63 - 85岁（平均67.1岁）的器质性勃起功能障碍男性。在这些患者中，180人首次接受前列腺素E1（PE）注射试验。随后，这180名患者和另外120名患者（共300名患者）接受了盐酸罂粟碱、甲磺酸酚妥拉明和前列腺素E1的三联组合（PPR）治疗。记录单独注射PE或药物组合后的有效反应者数量。勃起质量由医务人员在门诊进行评估，并通过患者在家试验后的报告进行评估。测量获得功能性勃起所需的PE或PPR的平均剂量。我们观察到，与PE相比，注射PPR后获得的结果之间存在统计学上的显著关联（自由度为2的卡方检验：34.666；P = < 0.001）。注射PPR后，300名患者中有224名（74.7%）获得了功能性勃起，而接受PE治疗的180名男性中有87名（48.3%）获得了功能性勃起。获得功能性勃起所需的PPR平均剂量为0.35±0.14毫升，而PE为1.3±0.3毫升。血管活性药物海绵体内注射仍然是患有器质性阳痿患者最成功的治疗方法之一。与年轻患者相比，它在老年组中的效果较差。然而，如果为老年男性选择这种治疗方式，三联组合疗法（PPR）产生的反应率高于单独使用前列腺素所获得的反应率。
